CHA
EBS icon

Carmichael Hill & Associates’s Emergent Biosolutions EBS Stock Holding History

Carmichael Hill & Associates’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-100
Closed -$9K – 778
2021
Q1 		$9K Buy
100
+50
+100% +$5.12K 0.01% 590
2020
Q4 		$4K Buy
+50
New +$4.59K ﹤0.01% 648

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Carmichael Hill & Associates's EBS Position: Q2 2021 in Review

Carmichael Hill & Associates sold out of Emergent Biosolutions (EBS) in Q2 2021, closing a stake of 100 shares — an estimated $9K sold.

Carmichael Hill & Associates first reported a position in EBS in Q4 2020 and held it in 2 quarters. The position peaked at $9K in Q1 2021. 290 funds tracked by Wall St. Rank hold EBS as of Q2 2021.

  • Carmichael Hill & Associates reported no remaining Emergent Biosolutions position as of Q2 2021 after selling out during the quarter.
  • Carmichael Hill & Associates sold 100 Emergent Biosolutions shares in Q2 2021, an estimated $9K.
  • Carmichael Hill & Associates first reported a position in Emergent Biosolutions in Q4 2020 and held it in 2 quarters.
  • Carmichael Hill & Associates's Emergent Biosolutions position peaked at $9K in Q1 2021.
  • 290 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2021.

Based on Carmichael Hill & Associates's 13F filing for Q2 2021, filed 3 Aug 2021.